Oncology · Clinical trials
Anal Cancer Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About anal cancer — and why its trials are hard
Anal cancer is an uncommon malignancy, most often squamous cell carcinoma of the anal canal, strongly linked to human papillomavirus (HPV) infection. Localized disease is managed with definitive chemoradiation (the Nigro protocol: 5-fluorouracil plus mitomycin with radiation), which is curative in many patients and avoids surgery. Systemic therapy for advanced, recurrent, or metastatic disease long relied on carboplatin/paclitaxel (established as the preferred first-line regimen in the InterAAct trial) or cisplatin/5-FU. Because these tumors are HPV-driven and immunogenic, checkpoint inhibitors have become central: retifanlimab, an anti-PD-1 antibody, is the first FDA-approved drug specifically for anal cancer, initially in previously treated disease and later in the first-line setting with chemotherapy. Nivolumab and pembrolizumab are guideline-recommended options in the second line based on single-arm data. The field remains small with few dedicated approvals, and durable responses to immunotherapy occur in only a minority, underscoring ongoing unmet need for biomarker-driven and combination strategies.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Retifanlimab (Zynyz) | 2023 | Previously treated, unresectable/metastatic squamous cell carcinoma of the anal canal (monotherapy) | POD1UM-202 (phase 2) | Overall response rate (accelerated approval) | ORR ~14%, with durable responses in responders |
| Retifanlimab (Zynyz) | 2025 | First-line, inoperable locally recurrent/metastatic anal canal SCC, with carboplatin + paclitaxel (also full approval as single agent) | POD1UM-303 (phase 3) | Progression-free survival | Statistically significant PFS improvement over chemotherapy alone |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in anal cancer development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Atezolizumab — SCARCE (GERCOR, phase 2, atezolizumab + modified DCF) | Adding atezolizumab to chemotherapy did not significantly improve progression-free survival | Unselected population; PD-L1 blockade plus chemotherapy insufficient to move the primary endpoint |
Choosing the right endpoint
Primary endpoints that matter in anal cancer trials
- Overall response rate (ORR) — Basis for retifanlimab's accelerated approval in previously treated disease (POD1UM-202)
- Progression-free survival (PFS) — Primary endpoint supporting first-line retifanlimab plus chemotherapy (POD1UM-303)
- Overall survival (OS) — Key secondary/confirmatory measure across advanced anal cancer trials
- Duration of response (DOR) — Important given checkpoint inhibitors produce durable responses in a minority of patients
- Locoregional/colostomy-free control — Central to curative chemoradiation trials in localized disease
How iNGENū runs anal cancer trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Anal Cancer clinical trials — FAQs
Is surgery the primary treatment for anal cancer?
What is the role of immunotherapy?
What is first-line chemotherapy for metastatic disease?
Ready to discuss your anal cancer trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal